MCID: INT079
MIFTS: 56

Intrahepatic Cholangiocarcinoma malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

Aliases & Descriptions for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 50 14 69
Cholangiocarcinoma 42 69
Peripheral Intrahepatic Cholangiocarcinoma 69
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
ICD10 33 C22.1
MeSH 42 D018281
NCIt 47 C35417
SNOMED-CT 64 109842005
UMLS 69 C0345905

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 50 intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. the terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. this condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation. last updated: 4/1/2014

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to colorectal cancer and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is MUC4 (Mucin 4, Cell Surface Associated), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Liver Extracts and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and endothelial, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 28.7 CDH1 CDX2 CTNNB1 EGFR EPCAM KRAS
2 sarcomatous intrahepatic cholangiocarcinoma 12.2
3 mucinous intrahepatic cholangiocarcinoma 12.1
4 signet ring cell intrahepatic cholangiocarcinoma 12.0
5 pigment dispersion syndrome 11.2
6 cholangiocarcinoma, susceptibility to 11.2
7 hepatitis 10.6
8 hepatocellular carcinoma 10.5
9 maternally-inherited cardiomyopathy and hearing loss 10.4 MUC2 MUC4 MUC5AC
10 choroid epithelioid cell melanoma 10.4 CDX2 MUC2 MUC5AC
11 thymus mucoepidermoid carcinoma 10.4 MUC1 MUC4 MUC5AC
12 myopathy, lactic acidosis, and sideroblastic anemia 2 10.4 MUC1 MUC2 MUC5AC
13 osteosarcoma arising in bone paget's disease 10.4 KRT19 KRT7 MUC5AC
14 breast adenocarcinoma 10.4 KRT19 KRT7 MUC5AC
15 linitis plastica 10.4 CDH1 TP53
16 secondary corneal edema 10.4 KRT19 MUC5AC TP53
17 precursor t-lymphoblastic lymphoma/leukemia 10.3 EGFR KRAS MUC1
18 fibular collateral ligament bursitis 10.3 MUC1 MUC2 MUC4 MUC5AC
19 eccrine papillary adenoma 10.3 AFP KRT19 KRT7
20 exudative glomerulonephritis 10.3 EGFR KRAS TP53
21 refractory plasma cell neoplasm 10.3 MUC1 MUC2 MUC4 MUC5AC
22 brachydactyly, type b1 10.3 MUC1 MUC2 MUC4 MUC5AC
23 anal carcinoma in situ 10.3 KRT19 KRT7 TP53
24 inhibited male orgasm 10.3 AFP KRAS TP53
25 ossifying fibromyxoid tumor 10.3 KRAS KRT19 TP53
26 paternal uniparental disomy of chromosome 1 10.3 EGFR IDH1 TP53
27 acute eustachian salpingitis 10.3 CDH1 CDX2 MUC2
28 hepatitis b 10.3
29 wolffian adnexal neoplasm 10.3 EGFR TP53
30 optic disk drusen 10.3 IDH1 IDH2
31 papilloma 10.3 CTNNB1 MUC1 MUC4
32 lymphedema 10.3 KRT19 MUC1 MUC4 MUC5AC
33 clitoris cancer 10.3 CDX2 KRT20 MUC1
34 cervix endometriosis 10.3 CDX2 KRT20 MUC2
35 nasal cavity adenocarcinoma 10.3 KRT7 MUC1 MUC4
36 childhood embryonal testis carcinoma 10.3 EGFR IDH1 TP53
37 testicular trophoblastic tumor 10.3 AFP KRAS MUC5AC
38 lung combined type small cell carcinoma 10.3 KRT19 KRT7 MUC1
39 testis refractory cancer 10.3 IDH1 IDH2 TP53
40 lateral sinus thrombosis 10.3 CDX2 KRT19 MUC2 MUC5AC
41 gastrointestinal system cancer 10.3 CDH1 MUC1 MUC2
42 cystinosis, nephropathic 10.3 IDH1 IDH2 TP53
43 strabismus 10.3 CTNNB1 MUC2 MUC5AC
44 breast ductal carcinoma 10.3 CTNNB1 KRAS TP53
45 arthus reaction 10.3 AFP KRAS TP53
46 spastic ataxia 5 10.3 CDX2 KRT20 TP53
47 mesenchymoma 10.3 CDX2 KRT20 MUC1
48 peritoneal benign neoplasm 10.3 CDX2 KRT20 KRT7
49 dystonia 10.3 CDX2 KRT20 KRT7
50 infiltrative basal cell carcinoma 10.3 CDH1 KRT19 KRT20

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 CTNNB1 EGFR KRAS MUC1 ADAM17
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 CTNNB1 EGFR EPCAM FGFR2 MUC1

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 ADAM17 CDH1 CDX2 CTNNB1 EGFR EPCAM
2 cellular MP:0005384 10.33 ADAM17 CDH1 CDX2 CTNNB1 EGFR EPCAM
3 homeostasis/metabolism MP:0005376 10.32 CTNNB1 EGFR EPCAM FGFR2 IDH1 KRAS
4 digestive/alimentary MP:0005381 10.31 ADAM17 CDH1 CDX2 CTNNB1 EGFR EPCAM
5 endocrine/exocrine gland MP:0005379 10.29 FGFR2 KRAS KRT19 MUC2 TP53 ADAM17
6 growth/size/body region MP:0005378 10.27 KRT19 MUC2 TP53 ADAM17 CDH1 CDX2
7 embryo MP:0005380 10.22 TP53 ADAM17 CDH1 CDX2 CTNNB1 EGFR
8 mortality/aging MP:0010768 10.22 ADAM17 AFP CDH1 CDX2 CTNNB1 EGFR
9 immune system MP:0005387 10.2 ADAM17 CDH1 CTNNB1 EGFR EPCAM FGFR2
10 neoplasm MP:0002006 10.11 CDH1 CDX2 CTNNB1 EGFR FGFR2 IDH2
11 limbs/digits/tail MP:0005371 10.03 ADAM17 CDX2 CTNNB1 EGFR FGFR2 IDH2
12 no phenotypic analysis MP:0003012 9.92 CDH1 CTNNB1 EGFR EPCAM FGFR2 KRAS
13 normal MP:0002873 9.91 CDH1 CDX2 CTNNB1 EGFR FGFR2 KRAS
14 reproductive system MP:0005389 9.65 ADAM17 AFP CDH1 CDX2 CTNNB1 EGFR
15 pigmentation MP:0001186 9.63 ADAM17 CTNNB1 EGFR FGFR2 KRAS TP53
16 skeleton MP:0005390 9.32 EGFR FGFR2 IDH1 IDH2 KRAS KRT19

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
2 Hematinics Phase 4,Phase 2
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
8
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
9
Succinylcholine Approved Phase 3,Phase 1 306-40-1 5314
10 Anti-Infective Agents Phase 3,Phase 2,Phase 1
11 Antimetabolites Phase 3,Phase 2,Phase 1
12 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
13 Antiviral Agents Phase 3,Phase 2,Phase 1
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
15 Alkylating Agents Phase 2, Phase 3
16 Antineoplastic Agents, Alkylating Phase 2, Phase 3
17 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
18 Neuromuscular Agents Phase 3,Phase 1
19 Neuromuscular Blocking Agents Phase 3,Phase 1
20 Neuromuscular Depolarizing Agents Phase 3,Phase 1
21
Fluorouracil Approved Phase 2 51-21-8 3385
22
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
24
Floxuridine Approved Phase 2,Phase 1 50-91-9 5790
25
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
26
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
27
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
28
chloroquine Approved, Vet_approved Phase 1, Phase 2 54-05-7 2719
29
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
30
nivolumab Approved Phase 2 946414-94-4
31
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
32
Ramucirumab Approved, Investigational Phase 2 947687-13-0
33
Ceritinib Approved Phase 2 1032900-25-6
34
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
35
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 134070 5280453
36
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 54575, 6560146 143
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
38
Doxil Approved June 1999 Phase 1, Phase 2 31703
39 Anti-Bacterial Agents Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 2,Phase 1
41 Bone Density Conservation Agents Phase 2
42 Calcium, Dietary Phase 2
43 Micronutrients Phase 2
44 Mitomycins Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
46 Trace Elements Phase 2
47 Vasoconstrictor Agents Phase 2
48 vitamin d Phase 2
49 Vitamins Phase 2
50 Antiemetics Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 71)
id Name Status NCT ID Phase
1 Stereotactic Body Radiotherapy for Liver Tumors Active, not recruiting NCT01347333 Phase 4
2 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3
3 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Recruiting NCT02548195 Phase 3
4 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3
5 Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT02200042 Phase 3
6 A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma Not yet recruiting NCT03081039 Phase 3
7 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Not yet recruiting NCT03086993 Phase 2, Phase 3
8 Calcitriol in Advanced Intrahepatic Cholangiocarcinoma Unknown status NCT01039181 Phase 2
9 Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma Unknown status NCT02415036 Phase 2
10 Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Unknown status NCT01247337 Phase 2
11 Regorafenib Versus Placebo to Treat Cholangiocarcinoma Unknown status NCT02162914 Phase 2
12 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2
13 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed NCT01954745 Phase 2
14 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2
15 A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy Completed NCT00587067 Phase 2
16 Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy Completed NCT01692704 Phase 1, Phase 2
17 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2
18 Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver Completed NCT00041808 Phase 1, Phase 2
19 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2
20 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2
21 Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma Completed NCT01389414 Phase 2
22 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin Recruiting NCT01648023 Phase 2
23 Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) Recruiting NCT01862315 Phase 2
24 Treatment for Bile Duct Cancer in the Liver Recruiting NCT02167711 Phase 2
25 Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Recruiting NCT02496741 Phase 1, Phase 2
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Recruiting NCT02392637 Phase 2
28 Ramucirumab for Advanced Pre-treated Biliary Cancers Recruiting NCT02520141 Phase 2
29 A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma Recruiting NCT02374489 Phase 2
30 Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). Recruiting NCT01798147 Phase 2
31 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Recruiting NCT02631590 Phase 2
32 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02428855 Phase 2
33 Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma Active, not recruiting NCT01912053 Phase 2
34 Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Active, not recruiting NCT01752920 Phase 1, Phase 2
35 Liver Transplantation for Early Intrahepatic Cholangiocarcinoma Not yet recruiting NCT02878473 Phase 2
36 A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma Not yet recruiting NCT02994251 Phase 2
37 Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer Not yet recruiting NCT03044587 Phase 2
38 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Not yet recruiting NCT02923934 Phase 2
39 Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma Terminated NCT02254681 Phase 2
40 Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION Terminated NCT01383746 Phase 1, Phase 2
41 Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer Terminated NCT00386516 Phase 2
42 Response of Hepatic Tumors to Radioembolization Withdrawn NCT01775280 Phase 2
43 Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Completed NCT01668134 Phase 1
44 Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma Recruiting NCT01525069 Phase 1
45 Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors Recruiting NCT02746081 Phase 1
46 Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder Recruiting NCT02375880 Phase 1
47 Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Active, not recruiting NCT01938729 Phase 1
48 Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases Active, not recruiting NCT00858429 Phase 1
49 Tremelimumab With Chemoembolization or Ablation for Liver Cancer Active, not recruiting NCT01853618 Phase 1
50 Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery Withdrawn NCT03117855 Phase 1

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

39
Liver, Lymph Node, Endothelial, Colon, Skeletal Muscle, T Cells, Kidney

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 713)
id Title Authors Year
1
Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. ( 28062160 )
2017
2
Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. ( 27893290 )
2017
3
The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. ( 28008570 )
2017
4
A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study. ( 28056836 )
2017
5
Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. ( 28045050 )
2017
6
The risk factors and prognostic factors of intrahepatic cholangiocarcinoma. ( 28089545 )
2017
7
Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. ( 28076328 )
2017
8
Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. ( 28345461 )
2017
9
TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma. ( 27554639 )
2016
10
Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. ( 27165138 )
2016
11
Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker. ( 27115053 )
2016
12
Recurrent Cardiac Tamponade: An Unusual Presentation of Intrahepatic Cholangiocarcinoma. ( 27144206 )
2016
13
Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. ( 27009864 )
2016
14
Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. ( 27152236 )
2016
15
Impact of Skeletal Muscle Mass, Muscle Quality, and Visceral Adiposity on Outcomes Following Resection of Intrahepatic Cholangiocarcinoma. ( 27837297 )
2016
16
Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis. ( 27068242 )
2016
17
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. ( 26868125 )
2016
18
Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis. ( 27046702 )
2016
19
TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-I_B pathway-mediated inflammatory responses. ( 27616304 )
2016
20
Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. ( 27654107 )
2016
21
Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. ( 27481548 )
2016
22
Down-Regulation of Nogo-B Expression as a Newly Identified Feature of Intrahepatic Cholangiocarcinoma. ( 26656426 )
2016
23
Intrahepatic cholangiocarcinoma coinciding with a liver metastasis from a rectal carcinoma: a case report. ( 27612869 )
2016
24
Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) originating from hepatic progenitor cell: a case report and review of the literature. ( 27535234 )
2016
25
Intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma -differentiation in terms of imaging diagnoses and surgical procedures. ( 27593364 )
2016
26
Intrahepatic cholangiocarcinoma in a patient with Wilson's disease: a case report. ( 27005296 )
2016
27
Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. ( 27170400 )
2016
28
Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. ( 27984655 )
2016
29
Members of the Cyr61/CTGF/NOV Protein Family: Emerging Players in Hepatic Progenitor Cell Activation and Intrahepatic Cholangiocarcinoma. ( 27829832 )
2016
30
ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. ( 26670746 )
2016
31
STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome. ( 28032598 )
2016
32
Clinicopathological differences between intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. ( 27593363 )
2016
33
Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. ( 27474881 )
2016
34
The differences between intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma -from diagnosis and biliary drainage points of view. ( 27593362 )
2016
35
Paraneoplastic fibrillary glomerulonephritis associated with intrahepatic cholangiocarcinoma: When diagnosis of a rare kidney disease leads to successful hepatic cancer treatment. ( 27542513 )
2016
36
EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma. ( 27469137 )
2016
37
Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings. ( 27193795 )
2016
38
A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. ( 27032374 )
2016
39
Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery. ( 27581609 )
2016
40
Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo. ( 27542675 )
2016
41
Synchronous pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma arising in the context of intraductal papillary neoplasms. ( 27183137 )
2016
42
Small Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in Cirrhotic Livers May Share Similar Enhancement Patterns at Multiphase Dynamic MR Imaging. ( 27077381 )
2016
43
Immunohistochemistry Using Monoclonal Antibody MsMab-2 Is Useful to Detect IDH1 R132L in Intrahepatic Cholangiocarcinoma. ( 27595804 )
2016
44
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma. ( 26765459 )
2016
45
The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: A clinicopathologic and immunohistochemical study. ( 27155908 )
2016
46
Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma. ( 27896410 )
2016
47
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. ( 27012989 )
2016
48
Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma. ( 27082702 )
2016
49
The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study. ( 26996383 )
2016
50
Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma. ( 27433094 )
2016

Variations for Intrahepatic Cholangiocarcinoma

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 ADAM17 CDH1 CTNNB1 EGFR FGFR2 IDH1
2
Show member pathways
13.57 ADAM17 CDH1 CTNNB1 EGFR FGFR2 IDH1
3
Show member pathways
13.46 CTNNB1 EGFR FGFR2 KRAS KRT19 KRT20
4
Show member pathways
12.96 CDH1 CTNNB1 EGFR FGFR2 KRAS TP53
5
Show member pathways
12.68 CDH1 CTNNB1 EGFR FGFR2 KRAS
6 12.51 CDH1 CTNNB1 EGFR FGFR2 KRAS TP53
7
Show member pathways
12.39 CTNNB1 EGFR FGFR2 KRAS TP53
8
Show member pathways
12.34 CDH1 CTNNB1 EGFR KRAS MUC1 TP53
9
Show member pathways
12.33 KRAS MUC1 MUC2 MUC4 MUC5AC
10 12.24 CTNNB1 EGFR KRAS TP53
11
Show member pathways
12.23 CDH1 CTNNB1 EGFR KRAS TP53
12 12.22 CDH1 EPCAM KRT19 KRT20 KRT7 MUC1
13
Show member pathways
12.19 MUC1 MUC2 MUC4 MUC5AC
14 12.18 ADAM17 AFP CDX2 CTNNB1
15
Show member pathways
12.13 EGFR FGFR2 KRAS TP53
16
Show member pathways
12.06 MUC1 MUC2 MUC4 MUC5AC
17 12.01 AFP CDX2 EPCAM KRT19
18 11.94 CDH1 CTNNB1 EGFR KRAS TP53
19 11.89 CTNNB1 EGFR KRAS TP53
20 11.88 CDH1 CTNNB1 EPCAM MUC1
21
Show member pathways
11.85 MUC1 MUC2 MUC4 MUC5AC
22 11.68 CDH1 CTNNB1 EGFR
23 11.62 CDH1 CTNNB1 EGFR KRAS RASGEF1A TP53
24 11.57 CDH1 EGFR KRAS TP53
25 11.43 ADAM17 EGFR FGFR2
26 11.37 CDH1 CTNNB1 EGFR
27 11.27 CTNNB1 EGFR TP53
28 11.21 CTNNB1 EGFR KRAS
29 10.92 CDH1 CTNNB1 KRAS TP53
30 10.83 EGFR FGFR2 IDH1 KRAS TP53

GO Terms for Intrahepatic Cholangiocarcinoma

Cellular components related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.26 CDH1 CTNNB1
2 flotillin complex GO:0016600 9.16 CDH1 CTNNB1
3 lateral plasma membrane GO:0016328 9.13 CDH1 CTNNB1 EPCAM
4 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC4 MUC5AC
5 extracellular exosome GO:0070062 10.02 CDH1 CTNNB1 EPCAM IDH1 IDH2 KRT19

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 epidermal growth factor receptor signaling pathway GO:0007173 9.65 ADAM17 EGFR KRAS
2 phosphatidylinositol-mediated signaling GO:0048015 9.62 EGFR FGFR2 MUC5AC TP53
3 maintenance of gastrointestinal epithelium GO:0030277 9.54 MUC2 MUC4
4 morphogenesis of embryonic epithelium GO:0016331 9.52 CTNNB1 FGFR2
5 entry of bacterium into host cell GO:0035635 9.51 CDH1 CTNNB1
6 positive regulation of cell proliferation GO:0008284 9.5 ADAM17 CDX2 CTNNB1 EGFR EPCAM FGFR2
7 lung-associated mesenchyme development GO:0060484 9.49 CTNNB1 FGFR2
8 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.46 ADAM17 EGFR
9 O-glycan processing GO:0016266 9.46 MUC1 MUC2 MUC4 MUC5AC
10 isocitrate metabolic process GO:0006102 9.43 IDH1 IDH2
11 cellular response to indole-3-methanol GO:0071681 9.4 CDH1 CTNNB1
12 mesenchymal cell proliferation involved in lung development GO:0060916 9.37 CTNNB1 FGFR2
13 glyoxylate cycle GO:0006097 9.26 IDH1 IDH2
14 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 KRAS MUC1 MUC2 MUC4 MUC5AC

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 CTNNB1 EGFR TP53
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
3 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....